Status:
WITHDRAWN
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
Amylin Pharmaceuticals, LLC.
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
Diabetes affects almost 21 million people in the United States. In this study we will test a drug called Pramlintide(Symlin), and see how it works to lower blood sugar and fat levels after a meal. Low...
Detailed Description
A well recognized and troublesome feature of diabetes management is the exacerbated post prandial glucose elevations following a typical high fat meal. To date the mechanisms driving this increased po...
Eligibility Criteria
Inclusion
- Type 2 DM study participants will be C-Peptide positive (levels \> 0.3 nmol/L)
- Receiving insulin, metformin and/or sulfonylurea/glitinide.
- Maintained on stable anti-hypertensive medication.
- BMI \< 52 kg/m2.
- T2DM for at least 3 months with HBA1C under 10%.
Exclusion
- Receiving TZDs, exenatide, sitagliptin or pramlintide therapy.
- Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
- Triglyceride levels \> 400 mg/dl.
- BMI \> 52 kg/m2.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00732147
Start Date
April 1 2009
End Date
April 1 2011
Last Update
July 22 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.